Literature DB >> 7339806

Clinical usefulness of amikacin and doxycycline in the treatment of infection due to Mycobacterium fortuitum and Mycobacterium chelonei.

J R Dalovisio, G A Pankey, R J Wallace, D B Jones.   

Abstract

The antimicrobial agents amikacin and doxycycline, which are not conventionally considered for use in treatment of mycobacterial infections, inhibit growth of Mycobacterium fortuitum and Mycobacterium chelonei in vitro. Ten patients were treated with these drugs alone or in combination with some surgical procedure. Seven of the 10 patients were definitely cured by the therapy. Only one definite treatment failure occurred. Patients with infections due to M. fortuitum or M. chelonei that are susceptible in vitro to these drugs appear to benefit from chemotherapy.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7339806     DOI： 10.1093/clinids/3.5.1068

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN： 0162-0886


  25 in total

1.  Multisite reproducibility of Etest for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum.

Authors:  G L Woods; J S Bergmann; F G Witebsky; G A Fahle; B Boulet; M Plaunt; B A Brown; R J Wallace; A Wanger
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

2.  A case of prolonged urinary tract infection caused by Mycobacterium fortuitum.

Authors:  I Hochman; Y Siegman-Igra; Y Goor; S Cabili
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-08       Impact factor: 3.267

Review 3.  Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.

Authors:  Barbara A Brown-Elliott; Kevin A Nash; Richard J Wallace
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

Review 4.  Epidemiology of infection by nontuberculous mycobacteria.

Authors:  J O Falkinham
Journal:  Clin Microbiol Rev       Date:  1996-04       Impact factor: 26.132

5.  Activities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single-drug therapy.

Authors:  R J Wallace; G Bedsole; G Sumter; C V Sanders; L C Steele; B A Brown; J Smith; D R Graham
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

6.  Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria.

Authors:  Richard J Wallace; Barbara A Brown-Elliott; Christopher J Crist; Linda Mann; Rebecca W Wilson
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

7.  Activities of the glycylcyclines N,N-dimethylglycylamido-minocycline and N,N-dimethylglycylamido-6-demethyl-6-deoxytetracycline against Nocardia spp. and tetracycline-resistant isolates of rapidly growing mycobacteria.

Authors:  B A Brown; R J Wallace; G Onyi
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

8.  Tetracycline resistance determinants in Mycobacterium and Streptomyces species.

Authors:  Y Pang; B A Brown; V A Steingrube; R J Wallace; M C Roberts
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

9.  Agar disk elution method for susceptibility testing of Mycobacterium marinum and Mycobacterium fortuitum complex to sulfonamides and antibiotics.

Authors:  M S Stone; R J Wallace; J M Swenson; C Thornsberry; L A Christensen
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

10.  Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae.

Authors:  J M Swenson; R J Wallace; V A Silcox; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.